Preclinical Models of Brain Metastases in Breast Cancer
Breast cancer remains a leading cause of mortality among women worldwide. Brain metastases confer extremely poor prognosis due to a lack of understanding of their specific biology, unique physiologic and anatomic features of the brain, and limited treatment strategies. A major roadblock in advancing...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945440/ https://www.ncbi.nlm.nih.gov/pubmed/35327469 http://dx.doi.org/10.3390/biomedicines10030667 |
_version_ | 1784673959053099008 |
---|---|
author | Knier, Natasha N. Pellizzari, Sierra Zhou, Jiangbing Foster, Paula J. Parsyan, Armen |
author_facet | Knier, Natasha N. Pellizzari, Sierra Zhou, Jiangbing Foster, Paula J. Parsyan, Armen |
author_sort | Knier, Natasha N. |
collection | PubMed |
description | Breast cancer remains a leading cause of mortality among women worldwide. Brain metastases confer extremely poor prognosis due to a lack of understanding of their specific biology, unique physiologic and anatomic features of the brain, and limited treatment strategies. A major roadblock in advancing the treatment of breast cancer brain metastases (BCBM) is the scarcity of representative experimental preclinical models. Current models are predominantly based on the use of animal xenograft models with immortalized breast cancer cell lines that poorly capture the disease’s heterogeneity. Recent years have witnessed the development of patient-derived in vitro and in vivo breast cancer culturing systems that more closely recapitulate the biology from individual patients. These advances led to the development of modern patient-tissue-based experimental models for BCBM. The success of preclinical models is also based on the imaging technologies used to detect metastases. Advances in animal brain imaging, including cellular MRI and multimodality imaging, allow sensitive and specific detection of brain metastases and monitoring treatment responses. These imaging technologies, together with novel translational breast cancer models based on patient-derived cancer tissues, represent a unique opportunity to advance our understanding of brain metastases biology and develop novel treatment approaches. This review discusses the state-of-the-art knowledge in preclinical models of this disease. |
format | Online Article Text |
id | pubmed-8945440 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89454402022-03-25 Preclinical Models of Brain Metastases in Breast Cancer Knier, Natasha N. Pellizzari, Sierra Zhou, Jiangbing Foster, Paula J. Parsyan, Armen Biomedicines Review Breast cancer remains a leading cause of mortality among women worldwide. Brain metastases confer extremely poor prognosis due to a lack of understanding of their specific biology, unique physiologic and anatomic features of the brain, and limited treatment strategies. A major roadblock in advancing the treatment of breast cancer brain metastases (BCBM) is the scarcity of representative experimental preclinical models. Current models are predominantly based on the use of animal xenograft models with immortalized breast cancer cell lines that poorly capture the disease’s heterogeneity. Recent years have witnessed the development of patient-derived in vitro and in vivo breast cancer culturing systems that more closely recapitulate the biology from individual patients. These advances led to the development of modern patient-tissue-based experimental models for BCBM. The success of preclinical models is also based on the imaging technologies used to detect metastases. Advances in animal brain imaging, including cellular MRI and multimodality imaging, allow sensitive and specific detection of brain metastases and monitoring treatment responses. These imaging technologies, together with novel translational breast cancer models based on patient-derived cancer tissues, represent a unique opportunity to advance our understanding of brain metastases biology and develop novel treatment approaches. This review discusses the state-of-the-art knowledge in preclinical models of this disease. MDPI 2022-03-13 /pmc/articles/PMC8945440/ /pubmed/35327469 http://dx.doi.org/10.3390/biomedicines10030667 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Knier, Natasha N. Pellizzari, Sierra Zhou, Jiangbing Foster, Paula J. Parsyan, Armen Preclinical Models of Brain Metastases in Breast Cancer |
title | Preclinical Models of Brain Metastases in Breast Cancer |
title_full | Preclinical Models of Brain Metastases in Breast Cancer |
title_fullStr | Preclinical Models of Brain Metastases in Breast Cancer |
title_full_unstemmed | Preclinical Models of Brain Metastases in Breast Cancer |
title_short | Preclinical Models of Brain Metastases in Breast Cancer |
title_sort | preclinical models of brain metastases in breast cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945440/ https://www.ncbi.nlm.nih.gov/pubmed/35327469 http://dx.doi.org/10.3390/biomedicines10030667 |
work_keys_str_mv | AT kniernatashan preclinicalmodelsofbrainmetastasesinbreastcancer AT pellizzarisierra preclinicalmodelsofbrainmetastasesinbreastcancer AT zhoujiangbing preclinicalmodelsofbrainmetastasesinbreastcancer AT fosterpaulaj preclinicalmodelsofbrainmetastasesinbreastcancer AT parsyanarmen preclinicalmodelsofbrainmetastasesinbreastcancer |